| Drug Name | Atezolizumab |
|---|---|
| Other Drug Names | MPDL-3280A; RG-7446; RO 5541267; Tecentriq |
| Chemical Name | immunoglobulin G1-kappa, anti-[Homo sapiens CD274(programmed death ligand 1, PDL1, PD-L1, B7 homolog 1,B7H1)], humanized monoclonal antibody;gamma1 heavy chain (1-448) [humanized VH (Homo sapiens IGHV3-23*04 (86.70%) -(IGHD)-IGHJ4*01)[8.8.11] (1-118) -Homo sapiens IGHG1*03 (CH1 R120>K (215) (119-216), hinge (217-231), CH2 N84.4>A (298) (232-341), CH3 (342-446), CHS (447-448)) (119-448)],(221-214')-disulfide with kappa light chain (1’-214’)[humanized V-KAPPA (Homo sapiens IGKV1-5*01(87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (227-227":230-230")-bisdisulfide |
| Formula | C6446H9902N1706O1998S42 |
| Mol. Wt. | 144.6 kDa |
| CAS No. | 1380723-44-3 |
| UNII | 52CMI0WC3Y |
| Target-based Actions | Programmed cell death ligand 1 inhibitor |
| Highest Status | 临床三期 |
| Originator Company | Genentech,Roche |
| Structure |
 |
Extended Information